ARVN - Arvinas, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
New Haven,
United States
Type: Equity
ARVN price evolution
ARVN
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $160.3 | $93.5 | $317.2 | |
| Short term investments | $1073.9 | $1081.3 | $949.3 | |
| Net receivables | $14.8 | $10 | $7.1 | $7.2 |
| Inventory | ||||
| Total current assets | $1149.5 | $1256.7 | $1190.3 | $1280.2 |
| Long term investments | ||||
| Property, plant & equipment | $7.8 | $11.3 | $12.4 | $14 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $22.9 | $22.3 | $24.4 | |
| Total investments | $1073.9 | $1081.3 | $949.3 | |
| Total assets | $1167.1 | $1279.6 | $1212.6 | $1304.6 |
| Current liabilities | ||||
| Accounts payable | $93.6 | $78.1 | $76.4 | $92.2 |
| Deferred revenue | $599.2 | $523.9 | $549.2 | |
| Short long term debt | $1.2 | $1.5 | $1.9 | |
| Total current liabilities | $275.9 | $347.2 | $240.8 | $257.1 |
| Long term debt | $0.6 | $0.9 | $1.1 | $1.3 |
| Total noncurrent liabilities | $332.2 | $362.1 | $387.5 | |
| Total debt | $2.1 | $2.6 | $3.2 | |
| Total liabilities | $581.1 | $679.4 | $602.9 | $644.6 |
| Shareholders' equity | ||||
| Retained earnings | -$1486.5 | -$1437.3 | -$1402.1 | -$1332.7 |
| Other shareholder equity | $4.1 | -$3.8 | -$4.4 | -$3.1 |
| Total shareholder equity | $600.2 | $609.7 | $660 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $317.2 | $86.8 | $112.8 | $588.37 |
| Short term investments | $949.3 | $1124 | $1394.3 | $100.16 |
| Net receivables | $7.2 | $8 | $25.7 | $8.44 |
| Inventory | ||||
| Total current assets | $1280.2 | $1240.2 | $1552.5 | $703.09 |
| Long term investments | ||||
| Property, plant & equipment | $14 | $17.8 | $16.6 | $14.25 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $24.4 | $28.6 | $29.1 | $14.28 |
| Total investments | $949.3 | $1124 | $1394.3 | $100.16 |
| Total assets | $1304.6 | $1268.8 | $1581.6 | $717.37 |
| Current liabilities | ||||
| Accounts payable | $92.2 | $5.7 | $31.3 | $7.12 |
| Deferred revenue | $549.2 | $623.7 | $740.5 | $45.09 |
| Short long term debt | $1.9 | $1.8 | $1.1 | $0.95 |
| Total current liabilities | $257.1 | $295.1 | $261.7 | $49.09 |
| Long term debt | $1.3 | $1 | $3.9 | $3.09 |
| Total noncurrent liabilities | $387.5 | $408.8 | $538.2 | $26.03 |
| Total debt | $3.2 | $5.5 | $5 | $4.04 |
| Total liabilities | $644.6 | $703.9 | $799.9 | $75.11 |
| Shareholders' equity | ||||
| Retained earnings | -$1332.7 | -$965.4 | -$682.9 | -$491.89 |
| Other shareholder equity | -$3.1 | -$19.2 | -$4.6 | $0.56 |
| Total shareholder equity | $660 | $564.9 | $781.7 | $642.26 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $102.4 | $76.5 | $25.3 | -$43.1 |
| Cost of revenue | ||||
| Gross Profit | $76.5 | $25.3 | -$43.1 | |
| Operating activities | ||||
| Research & development | $93.7 | $84.3 | $95.2 | |
| Selling, general & administrative | $31.3 | $24.3 | $27 | |
| Total operating expenses | $162.7 | $125 | $108.6 | $122.2 |
| Operating income | -$48.5 | -$83.3 | -$165.3 | |
| Income from continuing operations | ||||
| EBIT | -$35 | -$69.3 | -$153.2 | |
| Income tax expense | $0.6 | $0.2 | $0.1 | $1.6 |
| Interest expense | $14.3 | |||
| Net income | ||||
| Net income | -$49.2 | -$35.2 | -$69.4 | -$154.8 |
| Income (for common shares) | -$35.2 | -$69.4 | -$154.8 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $78.5 | $131.4 | $46.7 | $21.8 |
| Cost of revenue | ||||
| Gross Profit | $78.5 | $131.4 | $46.7 | $21.8 |
| Operating activities | ||||
| Research & development | $379.7 | $315 | $180.4 | $108.36 |
| Selling, general & administrative | $100.3 | $79.6 | $61.6 | $38.3 |
| Total operating expenses | $480 | $394.6 | $242 | $146.66 |
| Operating income | -$401.5 | -$263.2 | -$195.3 | -$124.86 |
| Income from continuing operations | ||||
| EBIT | -$366.4 | -$261.6 | -$190.9 | -$119.27 |
| Income tax expense | $0.9 | $20.9 | ||
| Interest expense | $0.1 | $0.07 | ||
| Net income | ||||
| Net income | -$367.3 | -$282.5 | -$191 | -$119.33 |
| Income (for common shares) | -$367.3 | -$282.5 | -$191 | -$119.33 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$35.2 | -$69.4 | -$154.8 | |
| Operating activities | ||||
| Depreciation | $1.7 | $1.7 | $1.7 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $21.6 | $18.6 | $16.7 | |
| Total cash flows from operations | $50.3 | -$97.5 | -$83.1 | |
| Investing activities | ||||
| Capital expenditures | -$0.6 | -$0.1 | -$0.1 | |
| Investments | $13.7 | -$127.7 | -$53.6 | |
| Total cash flows from investing | -$64.2 | $13.1 | -$127.8 | -$53.7 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $3.5 | $1.8 | $334.8 | |
| Net borrowings | -$0.1 | -$0.2 | ||
| Total cash flows from financing | $7.4 | $3.4 | $1.6 | $334.8 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$232 | $66.8 | -$223.7 | $198 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$367.3 | -$282.5 | -$191 | -$119.33 |
| Operating activities | ||||
| Depreciation | $6.7 | $8.2 | $6 | $4.02 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $71.6 | $75.5 | $57.1 | $30.23 |
| Total cash flows from operations | -$347.8 | -$273.5 | $559.4 | -$89.76 |
| Investing activities | ||||
| Capital expenditures | -$2.9 | -$6.8 | -$4.7 | -$6.45 |
| Investments | $206.4 | $249.6 | -$1308.9 | $170.7 |
| Total cash flows from investing | $203.5 | $242.8 | -$1313.6 | $164.25 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $374.7 | $4.7 | $278.6 | $504.67 |
| Net borrowings | ||||
| Total cash flows from financing | $374.7 | $4.7 | $278.6 | $504.67 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $230.4 | -$26 | -$475.6 | $579.16 |
News
Fundamentals
| Market cap | $1.27B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 68.70M |
| Revenue | $161.10M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$308.60M |
| Revenue Q/Q | 195.95% |
| Revenue Y/Y | -3.65% |
| P/E ratio | -4.11 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 7.88 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$4.49 |
|---|---|
| ROA | -24.87% |
| ROE | N/A |
| Debt/Equity | 0.98 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 4.17 |
| Quick ratio | N/A |